• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《圣乔治呼吸问卷在肺结节病中的应用》。

The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis.

机构信息

Janssen Research and Development, LLC, Raritan, USA.

The University of North Carolina, Chapel Hill, NC, USA.

出版信息

Lung. 2020 Dec;198(6):917-924. doi: 10.1007/s00408-020-00394-7. Epub 2020 Sep 26.

DOI:10.1007/s00408-020-00394-7
PMID:32979072
Abstract

RATIONALE

The Saint George's Respiratory Questionnaire (SGRQ) is a frequently used tool to assess health status in pulmonary disease patients. However, its performance characteristics in sarcoidosis patients are not well characterized.

METHODS

Data from a clinical trial of 138 symptomatic adults with sarcoidosis were used to examine the performance characteristics of SGRQ. Data were available at both baseline and week 24. Other assessments included FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6-min walk distance (6MWD), and Short Form-36 Physical Component Summary (SF-36 PCS) score.

RESULTS

Baseline SGRQ was 46.8, indicating impaired health status. At baseline, SGRQ total score correlated significantly with % predicted FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6MWD, and SF-36 PCS (r =  - 0.37, - 0.32, 0.57, 0.40, - 0.55, and - 0.80, respectively, p < 0.001). Change from baseline in SGRQ score also statistically significantly correlated with change from baseline in these parameters at week 24: r =  - 0.25, - 0.20, 0.30, 0.22, - 0.20, - 0.45, respectively (p < 0.05).

CONCLUSIONS

The SGRQ correlated with other outcome measures in sarcoidosis initially and with treatment. Improvement in FVC % predicted correlated with improvement in SGRQ. These data suggest the SGRQ may function as a reliable endpoint in clinical sarcoidosis trials.

摘要

背景

圣乔治呼吸问卷(SGRQ)是一种常用于评估肺部疾病患者健康状况的工具。然而,其在结节病患者中的性能特征尚未得到很好的描述。

方法

使用一项针对 138 例有症状结节病成人的临床试验数据来检验 SGRQ 的性能特征。数据在基线和 24 周时均可用。其他评估包括 FVC、FEV1、ATS 呼吸困难评分、Borg 的 CR 10 呼吸困难评分、6 分钟步行距离(6MWD)和健康调查简表 36 项躯体成分摘要(SF-36 PCS)评分。

结果

基线时 SGRQ 得分为 46.8,表明健康状况受损。基线时,SGRQ 总分与预计 FVC%、FEV1、ATS 呼吸困难评分、Borg 的 CR 10 呼吸困难评分、6MWD 和 SF-36 PCS 显著相关(r = -0.37、-0.32、0.57、0.40、-0.55 和 -0.80,p < 0.001)。从基线到 24 周的 SGRQ 评分变化也与这些参数从基线到 24 周的变化呈统计学显著相关:r = -0.25、-0.20、0.30、0.22、-0.20、-0.45,分别(p < 0.05)。

结论

SGRQ 与结节病的其他结局指标在初始和治疗时均相关。FVC%预计值的改善与 SGRQ 的改善相关。这些数据表明 SGRQ 可能作为结节病临床试验中的可靠终点。

相似文献

1
The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis.《圣乔治呼吸问卷在肺结节病中的应用》。
Lung. 2020 Dec;198(6):917-924. doi: 10.1007/s00408-020-00394-7. Epub 2020 Sep 26.
2
C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.C反应蛋白可预测慢性结节病患者对英夫利昔单抗的反应。
Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(1):49-56.
3
Physical Activity and Fatigue in Patients with Sarcoidosis.结节病患者的体力活动与疲劳。
Respiration. 2018;95(1):18-26. doi: 10.1159/000481827. Epub 2017 Nov 9.
4
Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis.二期慢性肺结节病抗分枝杆菌治疗疗效研究。
Chest. 2021 May;159(5):1902-1912. doi: 10.1016/j.chest.2020.12.027. Epub 2020 Dec 30.
5
Six-minute walk test and health status assessment in sarcoidosis.结节病的六分钟步行试验与健康状况评估
Chest. 2007 Jul;132(1):207-13. doi: 10.1378/chest.06-2822.
6
American translation, modification, and validation of the St. George's Respiratory Questionnaire.圣乔治呼吸问卷的美国版翻译、修改及验证
Clin Ther. 2000 Sep;22(9):1121-45. doi: 10.1016/S0149-2918(00)80089-2.
7
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.英夫利昔单抗治疗慢性结节病合并肺部受累患者。
Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802. doi: 10.1164/rccm.200603-402OC. Epub 2006 Jul 13.
8
Correlations between disease-specific and generic health status questionnaires in patients with advanced COPD: a one-year observational study.在晚期 COPD 患者中,疾病特异性和通用健康状况调查问卷之间的相关性:一项为期一年的观察性研究。
Health Qual Life Outcomes. 2012 Aug 21;10:98. doi: 10.1186/1477-7525-10-98.
9
Validation of a derived version of the IPF-specific Saint George's Respiratory Questionnaire.特发性肺纤维化特异性圣乔治呼吸问卷衍生版本的验证。
Respir Res. 2021 Oct 5;22(1):259. doi: 10.1186/s12931-021-01853-2.
10
The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis.结节病中呼吸困难、健康相关生活质量和心理因素之间的关系。
Respirology. 2014 Oct;19(7):1019-24. doi: 10.1111/resp.12359. Epub 2014 Aug 14.

引用本文的文献

1
Divergent perspectives: exploring the relationships between St. George's Respiratory Questionnaire and outcome measures in systemic sclerosis-associated interstitial lung disease.不同观点:探索圣乔治呼吸问卷与系统性硬化症相关间质性肺病的结局指标之间的关系。
Clin Rheumatol. 2024 May;43(5):1647-1656. doi: 10.1007/s10067-024-06950-3. Epub 2024 Apr 4.
2
D. Geraint James Lecture: The sarcoidosis saga: what insights from the past will guide us in the future.D. 杰兰特·詹姆斯讲座:结节病传奇:过去的哪些见解将在未来指引我们。
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023057. doi: 10.36141/svdld.v40i4.15282.
3

本文引用的文献

1
Endpoints for clinical trials of sarcoidosis.结节病临床试验的终点指标。
Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):90-8.
2
Ambrisentan for sarcoidosis associated pulmonary hypertension.安立生坦用于结节病相关的肺动脉高压。
Sarcoidosis Vasc Diffuse Lung Dis. 2011 Oct;28(2):139-45.
3
Inhaled iloprost for sarcoidosis associated pulmonary hypertension.吸入用伊洛前列素治疗结节病相关性肺动脉高压。
Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study.
结节病相关性肺动脉高压(SAPH)患者的肺动脉高压症状和影响问卷(PAH-SYMPACT™)的症状、影响和适用性:一项定性访谈研究。
BMC Pulm Med. 2021 Nov 12;21(1):365. doi: 10.1186/s12890-021-01694-1.
4
Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.罗沙司他治疗结节病相关性肺动脉高压:一项为期 1 年的双盲、安慰剂对照试验结果。
Chest. 2022 Feb;161(2):448-457. doi: 10.1016/j.chest.2021.07.2162. Epub 2021 Aug 4.
5
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.托法替布在肺结节病中的类固醇保肺治疗作用:一项开放性、前瞻性概念验证研究。
Lung. 2021 Apr;199(2):147-153. doi: 10.1007/s00408-021-00436-8. Epub 2021 Apr 7.
Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):110-20.
4
Psychophysical bases of perceived exertion.主观用力感觉的心理物理学基础。
Med Sci Sports Exerc. 1982;14(5):377-81.